Jan Veldink
Professor of Neurology and Neurogenetics
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Many non-coding variants influence complex traits and diseases through gene regulation, yet the mechanisms linking these variants to downstream biology remain poorly understood. Here, we present eQTLGen Phase 2 , a comprehensive genome-wide analysis of gene expression quantitative trait loci (eQTLs) in 43,301 blood samples from 52 datasets. Beyond local cis -effects, this sample size enabled the first systematic mapping of trans -eQTLs at scale. We identify cis -eQTLs for nearly all expressed genes (94.7%) and trans -eQTLs for over half (56.2%). Second, by colocalizing cis -eQTLs with trans -eQTLs, we infer a directed gene regulatory network comprising 47,554 directed gene regulatory relationships. These networks reveal how genetic perturbations in upstream regulators produce dose-dependent downstream effects, supported by Perturb-seq and ChIP-seq data. Third, integrating this network with 87 genome-wide association studies allows us to systematically prioritize trait-relevant pathways and candidate genes. Variants exerting both cis – and trans -effects are markedly more likely to colocalize with trait associations than cis -only variants, delineating a subset of functionally active cis -eQTLs from a large group with limited downstream impact. This distinction provides a conceptual framework for identifying regulatory variants that truly mediate complex trait biology. Together, these results provide a publicly available resource of cis – and trans -eQTLs and an in vivo scaffold for human gene-regulatory networks, elucidating how propagation of cis -effects modulates complex disease.
Year:
2026
Axonal and synaptic degeneration are key hallmarks of neurodegenerative diseases, but the underlying molecular mechanisms are incompletely understood. Here, we performed an unbiased forward genetic mosaic screen to identify genes required for maintenance of adult motor axons and neuromuscular junctions (NMJs) in the Drosophila leg. We identified 49 mutations in 30 genes, including mutations in 8 genes resulting in adult-onset progressive degeneration. We found that loss of pebbled ( peb ) function results in adult-onset motor axonal and NMJ degeneration, and age-dependent motor deficits. Peb is the Drosophila RREB1 ortholog, a C 2 H 2 zinc-finger transcription factor that negatively regulates transcription of RAS/MAPK pathway target genes. Loss of peb function resulted in excessive RAS/MAPK pathway activation, and loss of function of other negative regulators of the RAS/MAPK pathway also induced adult-onset progressive NMJ degeneration and motor deficits. Importantly, treatment of adult flies with the MEK1/2 inhibitor mirdametinib induced a dosage-dependent rescue of peb mutant motor neurodegenerative phenotypes. Thus, RAS/MAPK pathway overactivation results in adult-onset progressive neurodegeneration, which can be prevented by RAS/MAPK pathway inhibition.
Year:
2025
A variety of common and rare genetic factors have been implicated in the development of amyotrophic lateral sclerosis (ALS), and the evidence is that a genetic component is present in most affected individuals. However, our current understanding of ALS genetics causally explains only a small proportion of sporadic cases which represent over 90% of all people with ALS. This limits the utility of genetic testing in screening, diagnosis and management to the 15-20% of people with ALS who carry a known pathogenic variant. Capsule Networks (CapsNets) constitute a deep learning method that has demonstrated strong performance in using genotyping data to predict individuals at risk for ALS. However, their use is constrained by a lack of generalised, flexible, and validated implementations across comprehensive datasets that account for the technical, biological, and clinical heterogeneity found in real-world disease scenarios. In this study, we build upon this method to address existing limitations, to develop a new model that is validated across diverse ALS populations, can handle discrepancies between genotyping technologies, and is applicable to individual external samples. Using large-scale datasets from over 47,000 individuals from 13 countries, genotyped with nine different genotyping platforms, our model achieved high precision and sensitivity in distinguishing between individuals with ALS and non-affected controls. Moreover, in simulations of population screening for ALS, its performance was comparable to that of conventional genetic screening for known ALS gene mutations, such as FUS and C9orf72 . Our results demonstrate that this flexible and validated method could support the development of a genetic screening test for identifying individuals at risk and expediting ALS diagnosis. This would be applicable to all individuals, regardless of their family history or presence of known ALS mutations.
Year:
2025
Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) are both associated with a CAG-repeat expansion in ATXN2 and with TDP-43-positive neuronal cytoplasmic inclusions. The two disorders have been viewed as distinct entities, where an intermediate length expansion of 31–33 CAG-repeats is associated with sporadic ALS and a full length expansion of ≧ 34 CAG-repeats is associated with SCA2. We report the clinical phenotype of ATXN2 -positive patients and their relatives, identified in three specialist ALS clinics, which force a reconsideration of this dichotomy. We also report the frequency of ATXN2 expansions in two large cohorts of ALS patients and in a population-matched cohort of controls. We report ten cases of familial ALS in which disease is associated with either an intermediate or a full-length ATXN2 CAG-repeat expansion. Pedigrees and patients feature additional phenotypes including parkinsonism, dementia and essential tremor (ET). We conclude that CAG-repeat expansions in ATXN2 exhibit pleiotropy and are associated with a disease spectrum that includes ALS, SCA2, and parkinsonism; to recognise this complexity we propose the new term ‘ ATXN2 spectrum disorder’. We also observed sporadic ALS associated with full-length expansions. We conclude that ATXN2 CAG-repeat expansions, irrespective of length, should be considered a risk factor for both familial and sporadic ALS. Interrupted CAG-repeats were not perfectly aligned with an ALS phenotype in our data. Our findings have relevance for researchers, patients and families linked to CAG-repeat expansions in ATXN2 .
Year:
2024
Spinal muscular atrophy (SMA) is a severe neurodegenerative disease caused by defects in the survival motor neuron 1 ( SMN1 ) gene. The wide variability in SMA severity is partially explained by an inverse correlation with copy number variation of the second human SMN gene ( SMN2 ). Nevertheless, significant variability in severity and treatment response remains unexplained, prompting a search for accessible biomarkers that could explain and predict this variability. DNA methylation of SMN2 has been proposed as one such biomarker, but comprehensive evidence and analyses are lacking. Here, we combined long-read nanopore sequencing with targeted bisulfite sequencing to enable high-resolution analysis of SMN2 -specific methylation patterns. We observed tissue-specific variation in DNA methylation across the entire 30 kb SMN2 gene in 29 patients analyzed by long-read nanopore sequencing, identifying variable methylation patterns in the promoter, introns, and 3’ UTR. Subsequent targeted analysis of these regions by bisulfite sequencing of blood-derived DNA in 365 SMA patients showed no association between SMN2 methylation and disease severity or treatment response, excluding blood methylation patterns as predictive biomarkers. However, we discovered significant age-associated variation in SMN2 methylation, particularly in intron 1 and the 3’ UTR, highlighting DNA methylation as a possible modifier of SMN expression during development and aging. Our approach provides a broadly applicable strategy for detailed but cost-effective and high-throughput characterization of DNA methylation in other genes and diseases, including complex genetic regions.
Year:
2024
Sex is an important covariate in all genetic and epigenetic research due to its role in the incidence, progression and outcome of many phenotypic characteristics and human diseases. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with a sex bias towards higher incidence in males. Here, we report for the first time a blood-based epigenome-wide association study meta-analysis in 9274 individuals after stringent quality control (5529 males and 3975 females). We identified a total of 226 ALS saDMPs (sex-associated DMPs) annotated to a total of 159 unique genes. These ALS saDMPs were depleted at transposable elements yet significantly enriched at enhancers and slightly enriched at 3’UTRs. These ALS saDMPs were enriched for transcription factor motifs such as ESR1 and REST. Moreover, we identified an additional 10 genes associated with ALS saDMPs through chromatin loop interactions, suggesting a potential regulatory role for these saDMPs on distant genes. Furthermore, we investigated the relationship between DNA methylation at specific CpG sites and overall survival in ALS using Cox proportional hazards models. We identified two ALS saDMPs, cg14380013 and cg06729676, that showed significant associations with survival. Overall, our study reports a reliable catalogue of sex-associated ALS saDMPs in ALS and elucidates several characteristics of these sites using a large-scale dataset. This resource will benefit future studies aiming to investigate the role of sex in the incidence, progression and risk for ALS.
Year:
2024
The complex 2 Mb survival motor neuron (SMN) locus on chromosome 5q13, including the spinal muscular atrophy (SMA)-causing gene SMN1 and modifier SMN2 , remains incompletely resolved due to numerous segmental duplications. Variation in SMN2 copy number, presumably influenced by SMN1 to SMN2 gene conversion, affects disease severity, though SMN2 copy number alone has insufficient prognostic value due to limited genotype-phenotype correlations. With advancements in newborn screening and SMN -targeted therapies, identifying genetic markers to predict disease progression and treatment response is crucial. Progress has thus far been limited by methodological constraints. To address this, we used targeted nanopore long-read sequencing to analyze copy-specific variation in SMN and neighboring genes. In 25 healthy controls, we identified single nucleotide variants (SNVs) specific to SMN1 and SMN2 haplotypes that could serve as gene conversion markers. In 31 SMA patients, 45% of haplotypes showed varying SMN1 to SMN2 gene conversion breakpoints, serving as direct evidence of gene conversion as a common genetic characteristic in SMA and prompting further investigation into gene conversion markers as disease modifiers. Our findings illustrate that both methodological advances and the analysis of patient samples are required to advance our understanding of complex genetic loci and address critical clinical challenges.
Year:
2024
Significantly more men develop amyotrophic lateral sclerosis (ALS) than women, and heritability is not uniform between male and female transmissions, together suggesting a role for sex in the genetic aetiology of the disease. We therefore performed sex-stratified genome-wide and transcriptome-wide analyses of ALS risk, identifying six novel sex-specific risk loci including MEF2C , which shows increased expression in female ALS motor neurones. X-chromosome analysis revealed an additional risk locus at IL1RAPL2 .
Year:
2024
Recently, large-scale case-control analyses have been prioritized in the study of ALS. Yet the same effort has not been put forward to investigate additive moderate phenotypic effects of genetic variants in genes driving ALS risk, despite case-level evidence suggesting a potential oligogenic risk model. Considering its direct clinical and therapeutic implications, a large-scale robust investigation of oligogenicity in ALS is greatly needed. Here, we leveraged the Project MinE ALS Sequencing Consortium genome sequencing datasets of individuals with ALS (n = 6711) and controls (n = 2391) to identify signals of association between oligogenicity in known ALS genes (n=26) and disease risk, as well as clinical outcomes. Applying regression models to a discovery and replication cohort, we observed that the risk imparted from carrying rare variants in multiple known ALS genes was significant and was greater than the risk associated with carrying only a single rare variant, both in the presence and absence of variants in the most well-established ALS genes, such as C9orf72 . However, in contrast to risk, the relationships between oligogenicity and ALS clinical outcomes, such as age of onset and survival, might not follow the same pattern as we did not observe any associations. Our findings represent the first large-scale, case-control assessment of oligogenic associations in ALS to date and confirm that oligogenic events involving known ALS risk genes are indeed relevant for the risk of disease in approximately 6% of ALS but not necessarily for disease onset and survival. This must be considered in genetic counselling and testing by ensuring the use of comprehensive gene panels even when a potential pathogenic variant has already been identified. Moreover, in the age of stratified medication and gene therapy, it supports the need of a complete genetic profile for the correct choice of therapy in all ALS patients.
Year:
2024
Collaborators (72)
Qingbo Wang
Associate Professor
University of Tokyo
Annique Claringbould
Assistant Professor
Erasmus MC
Sali M K Farhan
McGill University
Marie Loh
Assistant Professor
Lee Kong Chian School of Medicine
Javier Martin
Professor
Instituto de Parasitología y Biomedicina López-Neyra
Katie Burnham
University of Oxford
Vincenzo Silani
Director
University of Milan, School of Medicine
Sini Nagpal
Assistant Professor
Indian Institute of Technology, Bombay
Brenda WJH Penninx
Professor
-
René Pool
University of Amsterdam
Markus Scholz
Leipzig University
Ahmad Al Khleifat
King’s College London
Stephan Zuchner
University of Miami Miller School of Medicine
Farzana Jasmine
Staff Scientist
University of Chicago
Marta Eugenia Alarcón Riquelme
Scientific Director
Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica
Laura Raffield
Assistant Professor
University of North Carolina at Chapel Hill
Dirk Paul
Interim Head of PMB BioPharma
AstraZeneca UK Limited
Gijs van Haaften
Associate Professor
Universitair Medisch Centrum Utrecht
Jouke-Jan Hottenga
Senior Researcher
Hamad Bin Khalifa University
Roel A. Ophoff
Professor
University of California, Los Angeles
Ana Viñuela
Academic, Lecturer (Teaching and Research)
University of Dundee
Pashupati Mishra
Tampere University
Emma Elisabeth Davenport
Group Leader
Wellcome Sanger Institute
Patrik Verstreken
Group Leader, Director and Professor
KU Leuven
José Manuel Soria Fernández
Principal Investigator. Head of Group
Hospital de la Santa Creu i Sant Pau
Bradley Smith
King’s College London
Julian Knight
University of Oxford
Mika Kähönen
University of Tampere
Philip Van Damme
Director of Neuromuscular Reference Center
University Hospitals Leuven
Muhammad Kibriya
Research Associate Professor
University of Chicago
Alexander Teumer
Professor
University Medicine Greifswald
Mamede de Carvalho
-
Russell McLaughlin
Ussher Assistant Professor in Genome Analysis
Trinity College Dublin
philippe corcia
Professeur
Université François-Rabelais
Andrew Brown
Principal Investigator
University of Dundee
Toni Boltz
Massachusetts General Hospital
Johnathan Cooper‐Knock
Consultant Neurologist and Senior Lecturer in Neurogenetics
University of Sheffield
Zoltán Kutalik
Full Professor
University of Lausanne
Annette Schenck
full Prof
Radboud University Medical Center
Ammar Al-Chalabi
Professor of Neurology and Complex Disease Genetics
King’s College London
Katja Pahkala
Associate professor, Academy research fellow
University of Turku
Emma Raitoharju
Senior Researcher
University of Tampere
Ewout J. N. Groen
Associate professor
Universitair Medisch Centrum Utrecht
Grant Montgomery
Professorial Research Fellow
University of Queensland
Annette Peters
Chair of Epidemiology
Ludwig-Maximilians-Universität München
Christian Gilissen
Professor of Genome Bioinformatics
Universitair Medisch Centrum Utrecht
Kaur Alasoo
Associate Professor
University of Tartu
Erik Storkebaum
Scientific Director
Radboud Universiteit Donders Institute for Brain Cognition and Behaviour
Joachim Thiery
Dean of Medicine and UKSH Board for Research snd Education
Kiel University
Alexis Battle
Professor
Johns Hopkins University
Alexander Schönhuth
Bielefeld University
Holger Kirsten
Leipzig University
Guy A Rouleau
Professor
McGill University
Olli T. Raitakari
University of Turku
Jonathan Mill
Professor
University of Exeter
Leonard Van den Berg
Universitair Medisch Centrum Utrecht
Uwe Völker
Professor, Head of Department
Universitätsmedizin Greifswald
Suvi Rovio
Adjunct professor, senor researcher
University of Turku
Hanneke W. M. van Deutekom
Head of Bioinformatics
University Medical Center Groningen
Carlos Cruchaga
Professor
Washington University in St. Louis
Carla van der Kallen
University of Maastricht
Alfredo Iacoangeli
King’s College London
Terho Lehtimäki
University of Tampere
Greg Gibson
Regents Professor
Georgia Tech
Yukinori Okada
University of Tokyo
Marleen van Greevenbroek
University of Maastricht
Michael van Es
Utrecht University
Ciarán Michael Kelly
Lecturer in Human Genomics and Computational Biology
Royal College of Surgeons in Ireland
Yun Li
Professor
University of North Carolina
Dorret I Boomsma
Full professor
University of Amsterdam
Roy Straver
Senior Scientist
Universitair Medisch Centrum Utrecht
Takanori Hasegawa
Associate Professor
Institute of Science Tokyo
Make your next move.
Prepare your application
Review drafts before you send them.